Status:
COMPLETED
A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis
Lead Sponsor:
GlaxoSmithKline
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study is designed to compare a range of doses of SB-681323 with prednisolone, which has known effects on rheumatoid arthritis patients. By comparing the two drugs and their effects on blood prote...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Must have a diagnosis of RA according to the revised 1987 criteria of the American College of Rheumatology.
- Must have 3 or more swollen or 3 or more tender/painful joints at screening.
- Must be on stable weekly methotrexate (2.5mg - 25mg) for at least eight weeks prior to screening.
- Exclusion criteria:
- Must not be morbidly obese.
Exclusion
Key Trial Info
Start Date :
June 21 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 3 2006
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT00134693
Start Date
June 21 2005
End Date
August 3 2006
Last Update
July 31 2017
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Darlinghurst, New South Wales, Australia, 2010
2
GSK Investigational Site
Douglas, Queensland, Australia, 4814
3
GSK Investigational Site
Woolloongabba, Queensland, Australia, 4102
4
GSK Investigational Site
Daw Park, South Australia, Australia, 5041